Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Prozone-like phenomenon in travellers with fatal malaria: report of two cases.

Santos L, Pereira NR, Andrade P, Dias PF, Alves CL, Abreu C, Serrão R, Ribeiro M, Sarmento A.

J Infect Dev Ctries. 2015 Mar 15;9(3):321-4. doi: 10.3855/jidc.5454.

2.

Long-term persistence of zoster vaccine efficacy.

Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN; Shingles Prevention Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20.

PMID:
25416754
3.

Primary drug resistance at diagnosis of HIV-1 infection: a Portuguese cohort.

Pereira NR, Duro R, Piñero C, Figueiredo C, Santos AS, Soares J, Serrão R, Sarmento A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19761. doi: 10.7448/IAS.17.4.19761. eCollection 2014.

4.

Prevention of mother-to-child transmission: experience of a Portuguese centre.

Piñeiro C, Fernandes S, Figueiredo C, Santos AS, Moucho M, Serrão R, Montenegro N, Sarmento A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19705. doi: 10.7448/IAS.17.4.19705. eCollection 2014.

5.

Characterization of HIV-1 subtypes in a Portuguese cohort.

Pereira NR, Duro R, Piñero C, Malheiro L, Soares J, Serrão R, Sarmento A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19683. doi: 10.7448/IAS.17.4.19683. eCollection 2014.

6.

Mucinous carcinoma: a translucent blue papule on an 89-year-old man.

Hagele TJ, Chiang C, Serrao R, Trevino JJ.

Skinmed. 2013 Jul-Aug;11(4):254-5.

PMID:
24053014
7.

Acute hepatitis E complicated by Guillain-Barre syndrome in Portugal, December 2012--a case report.

Santos L, Mesquita JR, Rocha Pereira N, Lima-Alves C, Serrão R, Figueiredo P, Reis J, Simões J, Nascimento M, Sarmento A.

Euro Surveill. 2013 Aug 22;18(34). pii: 20563.

8.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group.

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.

9.

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group.

Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24.

10.

Multiples in dermatology: markers for special considerations in diagnosis, therapy, and prognosis.

Trevino J, Grosshandler J, Chen AY, Chiang C, Serrao R, Dohil M.

J Drugs Dermatol. 2012 Jul;11(7):812-7. Review.

PMID:
22777221
11.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team.

Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
12.

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.

Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R, Sola R, Bertasso A, Passe And S, Stancic S.

HIV Clin Trials. 2012 May-Jun;13(3):142-52. doi: 10.1310/hct1303-142.

PMID:
22592094
13.

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team.

Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18.

PMID:
22015077
14.

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults.

Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group.

J Am Geriatr Soc. 2010 Sep;58(9):1634-41. doi: 10.1111/j.1532-5415.2010.03021.x.

15.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

16.

A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM; Shingles Prevention Study Group.

J Med Virol. 2009 Jul;81(7):1310-22. doi: 10.1002/jmv.21506.

17.

Goeckerman treatment for remission of psoriasis refractory to biologic therapy.

Serrao R, Davis MD.

J Am Acad Dermatol. 2009 Feb;60(2):348-9. doi: 10.1016/j.jaad.2008.10.016. No abstract available.

PMID:
19150284
18.

Localized cutaneous mucinosis after joint replacement.

Haught JM, Serrao R, English JC 3rd.

Arch Dermatol. 2008 Oct;144(10):1399-400. doi: 10.1001/archderm.144.10.1399. No abstract available.

PMID:
18936415
19.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk